IMMUTEP LTD-SP ADR (IMMP) Stock News

NASDAQ:IMMP - Nasdaq - US45257L1089 - ADR - Currency: USD

1.8 +0.08 (+4.65%)

After market: 1.83 +0.03 (+1.67%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IMMP Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Yahoo Finance

Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data

a month ago - By: Immutep Limited

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

2 months ago - By: Immutep Limited

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

2 months ago - By: Benzinga - Mentions: CVM BCLI LIPO BDSX ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 months ago - By: Benzinga - Mentions: MRK

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

2 months ago - By: Immutep Limited

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

3 months ago - By: Immutep Limited

Immutep Quarterly Activities Report Q3 FY25

4 months ago - By: Immutep Limited

Immutep to Participate in Upcoming Investor Conferences

4 months ago - By: Immutep Limited

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

6 months ago - By: Immutep Limited

Immutep Quarterly Activities Report Q2 FY25

7 months ago - By: Immutep Limited

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

8 months ago - By: Immutep Limited

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

9 months ago - By: Immutep Limited

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

9 months ago - By: Immutep Limited

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

9 months ago - By: Immutep Limited

Immutep Quarterly Activities Report Q1 FY25

9 months ago - By: Immutep Limited

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

10 months ago - By: Immutep Limited

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

11 months ago - By: Immutep Limited

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

a year ago - By: Immutep Limited

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

a year ago - By: Immutep Limited

Immutep to Participate in Upcoming Investor Conferences

a year ago - By: Immutep Limited

Immutep Quarterly Activities Report Q4 FY24

a year ago - By: Immutep Limited

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

a year ago - By: InvestorPlace - Mentions: CGBS TOYO SNTG ABVE ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

a year ago - By: Immutep Limited

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

a year ago - By: Immutep Limited

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

a year ago - By: InvestorPlace - Mentions: IONM VIGL CASI ENTO ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

a year ago - By: Immutep Limited

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

a year ago - By: Immutep Limited

Immutep successfully completes institutional placement and institutional component of entitlement offer

a year ago - By: Immutep Limited

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial